BackDNA Brands Overview

DNA Brands EBIT

Latest ebit for DNAX: $-290K, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$80.03K
↓ 57.7% YoY

As of Sep 30, 2025

Annual EBIT (TTM)

-$290.62K
↑ 23.65% YoY

Trailing 12 months ending Sep 30, 2025

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

DNA Brands (DNAX) FAQ

The latest EBIT for DNAX is $-290K as of September 2025. That compares with $-380K in the prior-year period — up 23.6% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside DNA Brands's historical trend and sector peers before judging valuation or financial health.

Over the past year, DNAX's EBIT moved from $-380K to $-290K — a 23.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in DNA Brands's operating scale or balance-sheet position.

Against its sector companies, DNAX currently prints $-290K for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at DNA Brands's growth, margins, and balance sheet.

A EBIT figure of $-290K for DNAX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting DNAX's EBIT ($-290K), review year-over-year change from $-380K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.